These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 24036891

  • 1. Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting.
    d'Arminio Monforte A, Gianotti N, Cozzi-Lepri A, Pinnetti C, Andreoni M, di Perri G, Galli M, Poli A, Costantini A, Orofino G, Maggiolo F, Mazzarello G, Celesia BM, Luciani F, Lazzarin A, Sighinolfi L, Rizzardini G, Bonfanti P, Perno CF, Antinori A, ICONA Foundation Cohort.
    Antivir Ther; 2014; 19(3):319-24. PubMed ID: 24036891
    [Abstract] [Full Text] [Related]

  • 2. Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study.
    Gianotti N, Poli A, Galli M, Pan A, Rizzardini G, Soria A, Viale P, Di Biagio A, Quirino T, Viganò P, Bonfanti P, d'Arminio Monforte A, Fortino I, Lazzarin A.
    New Microbiol; 2014 Oct; 37(4):439-48. PubMed ID: 25387282
    [Abstract] [Full Text] [Related]

  • 3. Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
    Gianotti N, Cozzi-Lepri A, Antinori A, Castagna A, De Luca A, Celesia BM, Galli M, Mussini C, Pinnetti C, Spagnuolo V, d'Arminio Monforte A, Ceccherini-Silberstein F, Andreoni M, Icona Foundation Study and mono-PI/r database Study Cohorts.
    PLoS One; 2017 Oct; 12(2):e0171611. PubMed ID: 28192453
    [Abstract] [Full Text] [Related]

  • 4. Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting.
    Gianotti N, Cozzi-Lepri A, Antinori A, Di Biagio A, Moioli MC, Nozza S, Cingolani A, De Luca A, Madeddu G, Bonora S, Ceccherini-Silberstein F, Monforte Ad, ICONA Foundation Study.
    J Int AIDS Soc; 2014 Oct; 17(4 Suppl 3):19799. PubMed ID: 25397543
    [Abstract] [Full Text] [Related]

  • 5. A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients: the MONOCO study.
    Cooper C, la Porte C, Tossonian H, Sampalis J, Ackad N, Conway B.
    HIV Clin Trials; 2012 Oct; 13(4):179-88. PubMed ID: 22849960
    [Abstract] [Full Text] [Related]

  • 6. HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.
    Bunupuradah T, Bowonwattanuwong C, Jirajariyavej S, Munsakul W, Klinbuayaem V, Sophonphan J, Mahanontharit A, Hirschel B, Ruxrungtham K, Ananworanich J, HIV STAR Study team.
    Antivir Ther; 2014 Oct; 19(6):579-86. PubMed ID: 24464590
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
    Lathouwers E, De Meyer S, Dierynck I, Van de Casteele T, Lavreys L, de Béthune MP, Picchio G.
    Antivir Ther; 2011 Oct; 16(1):99-108. PubMed ID: 21311113
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
    Ortiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, Fourie J, De Meyer S, De Pauw M, Lefebvre E, Vangeneugden T, Spinosa-Guzman S.
    AIDS; 2008 Jul 31; 22(12):1389-97. PubMed ID: 18614861
    [Abstract] [Full Text] [Related]

  • 13. HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study).
    Hasson H, Galli L, Gallotta G, Neri V, Blanc P, D'Annunzio M, Morsica G, Sollima S, Merli M, Lazzarin A, Uberti-Foppa C.
    New Microbiol; 2012 Oct 31; 35(4):469-74. PubMed ID: 23109014
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Long-term lopinavir/ritonavir monotherapy in HIV-infected children.
    Kosalaraksa P, Ananworanich J, Puthanakit T, Pinyakorn S, Lumbiganon P, Chuanjaroen T, Chobkarjing U, Phanuphak P, Pancharoen C, Bunupuradah T, HIV-NAT 077 Study Team.
    Pediatr Infect Dis J; 2013 Apr 31; 32(4):350-3. PubMed ID: 23190774
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.